Key facts
- It has raised $340K; the latest was Angel (individual) ($230K) in Oct 2025.
- Notable investors include Agência Nacional de Inovação, Instituto Pedro Nunes, Portugal Telecom Inovacao, Portugal Ventures, SantanderX.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for expressTEC (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for expressTEC (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About expressTEC (Biotechnology)
Operator of a biotechnology startup intended to provide quick access to personalized therapies for cancer patients. The company developed RNA-based diagnostic tests to revolutionize clinical testing, selecting patients with greater precision and efficiency for targeted therapies, enabling patients to optimize treatment results.
- Sector
- Healthcare
- HQ
- Faro, Portugal
- Founded
- 2022
- Employees
- 7
- Website
- expresstec.pt/
- Ownership
- Privately Held (backing)
expressTEC (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in expressTEC (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on expressTEC (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.